Epigenetic targeting of EZH2, a histone-lysine-N-methyltransferase and DNMT1 inhibitor reactivated transcriptionally repressed chemokine genes and augmented T cell response in HCC (237). This evidence concerns the gene EZH2 and hepatocellular carcinoma.